Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β 1a in humans

Pharmaceutical Research

Volumn 19, Issue 10, 2002, Pages 1537-1543

  Mager, Donald E ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Humans; Interferon beta; Mathematical modeling; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA1A INTERFERON; NEOPTERIN; NEUTRALIZING ANTIBODY; RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; HUMAN; MALE; MATHEMATICAL MODEL; PHARMACODYNAMICS; PRIORITY JOURNAL;

FEMALE; HUMANS; INTERFERON-BETA; MALE; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 0036803408     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020468902694     Document Type: Article

References (25)

1. J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker. Multiple sclerosis. N. Engl. J. Med. 343:938-952 (2000).
2. W. Leonard. Type I cytokines and interferons and their receptors. In W. Paul (ed.), Fundamental Immunology, Lippincott-Raven, Philadelphia, Pennsylvania, 1999 pp. 741-774.
3. S. Pestka, J. A. Langer, K. C. Zoon, and C. E. Samuel. Interferons and their actions. Annu. Rev. Biochem. 56:727-777 (1987).
4. J. Alam, S. Goelz, P. Rioux, J. Scaramucci, W. Jones, A. McAllister, M. Campion, and M. Rogge. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. 14:546-549 (1997).
5. J. Chiang, C. A. Gloff, C. N. Yoshizawa, and G. J. Williams. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm. Res. 10:567-572 (1993).
6. G. Fierlbeck, A. Ulmer, T. Schreiner, W. Stroebel, U. Schiebel, and J. Brzoska. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. 16:777-781 (1996).
7. L. E. Rothuizen, T. Buclin, F. Spertini, I. Trinchard, A. Munafo, P. A. Buchwalder, A. Ythier, and J. Biollaz. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biologic effect markers. J. Neuroimmunology 99:131-141 (1999).
8. P. Salmon, J. Y. Le Cotonnec, A. Galazka, A. Abdul-Ahad, and A. Darragh. Pharmacokinetics and pharmacodynamics of recombinant human interferon- beta in healthy male volunteers. J. Interferon Cytokine Res. 16:759-764 (1996).
9. D. E. Mager, B. Neuteboom, A. Murafo, C. Efthymiopoulos, and W. J. Jusko. Receptor-mediated pharmacokinetics and pharmacodynamics of IFN-beta 1a following intravenous and subcutaneous dosing in monkeys. In Pharmaceutical Congress of the Americas. AAPS, Orlando, Florida, 2001.
10. D. E. Mager and W. J. Jusko. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28:507-532 (2001).
11. P. A. Buchwalder, T. Buclin, I. Trinchard, A. Munafo, and J. Biollaz. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 20:857-866 (2000).
12. K. C. Zoon and H. Arnheiter. Studies of the interferon receptors. Pharmacol. Ther. 24:259-278 (1984).
13. E. Radwanski, A. Chakraborty, S. Van Wart, R. D. Huhn, D. L. Cutler, M. B. Affrime, and W. J. Jusko. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm. Res. 15:1895-1901 (1998).
14. A. Supersaxo, W. Hein, and H. Steffen. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7:167-169 (1990).
15. D. Fuchs, G. Weiss, G. Reibnegger, and H. Wachter. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit. Rev. Clin. Lab. Sci. 29:307-341 (1992).
16. A. Sharma, W. F. Ebling, and W. J. Jusko. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J. Pharm. Sci. 87:1577-1584 (1998).
17. R. Braeckman. Pharmacokinetics and pharmacodynamics of protein therapeutics. In R. E. Reid (ed.), Peptide and Protein Drug Analysis, University of British Columbia, Vancouver, 1999 pp. 633-669.
18. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478 (1993).
19. H. Cheng, A. Staubus, and L. Shum. An area function method for estimating the apparent absorption rate constant. Pharm. Res. 5:57-60 (1988).
20. D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles, California, 1997.
21. S. D. Cook, J. R. Quinless, A. Jotkowitz, P. Beaton, and the Neutralizing Antibody Study Group. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 57:1080-1084 (2001).
22. Y. Sugiyama and M. Hanano. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res. 6:192-202 (1989).
23. G. Levy. Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56:248-252 (1994).
24. G. Stark, I. Kerr, B. Williams, R. Silverman, and R. Schreiber. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264 (1998).
25. A. M. Liberati, M. Fizzotti, M. G. Proietti, R. Di Marzio, M. Schippa, B. Biscottini, M. Senatore, P. Berruto, S. Canali, G. Peretti, and G. Zanolo. Biochemical host response to interferon-beta. J. Interferon Res. 8:765-777 (1988).